SCHEMBL1455417

SCHEMBL1455417

O=C(Nc1ccc(Sc2ccc(O)cc2)c(Nc2ncnc3ncccc23)c1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.46
KDR P35968 1/20 0.43
EGFR P00533 2/20 0.41
MAPK14 Q16539 2/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
PIM1 P11309 1/20 0.40
AKT2 P31751 1/20 0.40
CSF1R P07333 1/20 0.40
GRM4 Q14833 1/20 0.39
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455215 0.92 PIM1 (0.41) BRAFEGFRMAPK14MEN1NPC1
SCHEMBL1454907 0.88 PIM1 (0.45) BRAFKDREGFRMAPK14MEN1
SCHEMBL1454720 0.87 PIM1 (0.44) BRAFKDREGFRMAPK14PIM1
SCHEMBL1454908 0.87 EGFR (0.48) BRAFKDREGFRMEN1NPC1
SCHEMBL1455179 0.87 KCNQ3 (0.45) BRAFKDRPIM1AKT2AURKA
SCHEMBL1454780 0.87 PIM1 (0.45) BRAFKDREGFRMEN1KMT2A
SCHEMBL1455767 0.86 PIM1 (0.46) BRAFEGFRMAPK14NPC1MAPT
SCHEMBL1454978 0.86 PIM1 (0.43) BRAFKDREGFRMAPK14KDM4E
SCHEMBL1454672 0.85 BRAF (0.48) BRAFKDREGFRMEN1NPC1
SCHEMBL1454471 0.85 PIM1 (0.42) BRAFMAPK14PIM1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 BRAF 4226/4885KDR 3293/4885EGFR 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.